To address these limitations, we propose a novel strategy for profiling EGFR mutations at the protein level by directly detecting mutant EGFR protein on CTCs, which may effectively overcome the challenges posed by tumor heterogeneity. This evidence concerns the gene EGFR and neoplasm.